Johnson Pharmacare Share News - Latest Updates, Live News & More

Latest news about Johnson Pharmacare

Johnson Pharmacare Limited Reports Q3 FY26 Financial Results with Net Loss of 6.40 Lakhs 6 days ago

Johnson Pharmacare Limited reported Q3 FY26 results showing a net loss of 6.40 lakhs compared to 2.99 lakhs loss in the corresponding quarter of previous year. The company recorded zero revenue from operations with total expenses of 6.40 lakhs, primarily driven by finance costs of 4.01 lakhs and other expenses of 2.18 lakhs. For nine months ended December 2025, cumulative losses increased to 12.34 lakhs from 7.06 lakhs in the corresponding previous period.

Johnson Pharmacare Board Approves Independent Director Appointment with Regulatory Compliance 7 days ago

Johnson Pharmacare Limited Appoints Mr. Umesh Kumar as Additional Executive Director Feb 09, 2026

Johnson Pharmacare Limited Announces Resignation of Additional & Executive Director Umesh Kumar Jan 31, 2026

Johnson Pharmacare Limited Announces Resignation of Two Directors Effective January 21, 2026 Jan 21, 2026

More news about Johnson Pharmacare

15Jan 26

Johnson Pharmacare Limited Announces Resignation of Statutory Auditor Effective January 15, 2026

Johnson Pharmacare Limited announced the resignation of statutory auditor M/s Rishi Sekhri and Associates Chartered Accountants effective January 15, 2026, due to preoccupation with other assignments. The auditor served from September 4, 2017, with their term originally scheduled to expire March 31, 2024, and submitted their latest audit report on November 14, 2025. The company has completed all regulatory disclosures under SEBI LODR Regulations, and the auditor provided a no-objection certificate for future auditor appointments.

08Jan 26

Johnson Pharmacare Limited Relocates Registered Office to Navrangpura, Ahmedabad

Johnson Pharmacare Limited has relocated its registered office from Bodakdev to Navrangpura area in Ahmedabad, effective January 8, 2026. The move was approved by the Board of Directors and has been filed with the Registrar of Companies with all statutory approvals obtained. The company disclosed this change in compliance with SEBI regulations.

24Nov 25

Johnson Pharmacare Limited Establishes New Corporate Office in New Delhi

Johnson Pharmacare Limited's Board of Directors has approved the establishment of a new Corporate Office in New Delhi. The office, located at 1002 10th Floor, Vikram Tower, Rajendra Place, will support centralized management, administration, and operational functions. Director Umesh Kumar has been authorized to oversee the setup. The decision was made during a board meeting on November 24, 2025, from 5:00 PM to 5:30 PM. This move aims to enhance the company's operational capabilities and administrative efficiency.

15Nov 25

Johnson Pharmacare Reports Loss in H1 FY2026 Amid Ongoing Financial Challenges

Johnson Pharmacare Limited reported a loss before tax of Rs. 5.68 lakhs for the six-month period ending September 30, 2025. In Q1 FY2026, the company had zero revenue, compared to a negative revenue of Rs. 0.30 crore in Q4 FY2025. EBITDA loss reduced to Rs. 0.10 crore from Rs. 0.50 crore, and net loss narrowed to Rs. 0.10 crore from Rs. 0.50 crore in the previous quarter. EPS improved from -0.01 to 0.00. The results were approved by the Board of Directors on November 14, 2025, and have undergone a limited review by statutory auditors.

27Oct 25

Johnson Pharmacare Limited Announces Director Paresh Sengal's Resignation

Johnson Pharmacare Limited announced the resignation of Mr. Paresh Sengal from his position as Director, effective October 27, 2025. The resignation was accepted during a board meeting held at the company's registered office. Mr. Sengal cited preoccupation with other work as the reason for his departure. The company, listed on BSE with scrip code 532154 and security ID JOHNPHARMA, has informed the BSE about this development in compliance with SEBI regulations.

23Jul 25

Johnson Pharmacare Reports Wider Net Loss in Q1 FY2026, Expenses Rise

Johnson Pharmacare Limited reported a net loss of Rs. 5.34 lacs for Q1 FY2026, compared to Rs. 3.99 lacs in Q1 FY2025. The company had no revenue from operations, while total expenses increased to Rs. 5.34 lacs from Rs. 3.99 lacs year-over-year. Other expenses rose to Rs. 5.04 lacs, and employee benefit expenses were Rs. 0.30 lacs. The company's paid-up equity share capital remains at Rs. 5,500 lacs. The Board of Directors approved these unaudited results on July 23, 2025, after review by the Audit Committee and limited review by statutory auditors.

01Apr 25

Johnson & Johnson's Talc Claims Bankruptcy Plan Rejected for Third Time

Johnson & Johnson's $9 billion trust fund proposal to settle talc-related cancer claims through bankruptcy has been rejected by a federal judge due to flawed voting procedures. This dismissal, the third such attempt, potentially exposes J&J to continued lawsuits in the traditional court system. The decision could lead to increased legal costs, prolonged financial uncertainty, and possible reputational damage for the company as it faces thousands of talc-related lawsuits alleging its products caused cancer.

12Mar 25

Johnson & Johnson Secures ₹3.34 Crore Victory in Delhi High Court Counterfeit Case

Johnson & Johnson has won a significant legal battle against counterfeit medical products in India. The Delhi High Court awarded J&J ₹3.34 crore in damages and issued a permanent injunction against the defendants for manufacturing and selling fake surgical products under J&J's trademarks. The court emphasized the public health risks posed by counterfeit medical products. This ruling reinforces J&J's brand protection efforts, commitment to patient safety, and sends a strong message to counterfeiters in the healthcare industry.

19Feb 25

Johnson & Johnson Faces Crucial Moment in $9 Billion Baby Powder Settlement

Johnson & Johnson is seeking approval for a $9 billion settlement to resolve lawsuits claiming its baby powder caused cancer. A lawyer representing 20,000 women is urging the court to approve the settlement. J&J's use of Chapter 11 bankruptcy strategy has faced opposition, including from the U.S. Trustee. The pre-bankruptcy voting process has also been questioned. If approved, this would be one of the largest mass tort litigation settlements in U.S. history, potentially allowing J&J to move past the controversy.